Stock Quote
Par Pharmaceutical Companies, Inc. (PRX) (NYSE Arca)
$24.03
2:40pm EST
+2.47%
$23.45
$23.74
538,397
$24.15
$23.66
$24.23
$8.57
0.73
611,268
PRX
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| LePore, Patrick | Chairman of the Board, President, Chief Executive Officer | 2,577,350 |
| Kenyon, Lawrence | Chief Financial Officer, Executive Vice President | -- |
| Haughey, Thomas | Executive Vice President, Chief Administrative Officer, General Counsel, Secretary | 1,651,640 |
Profile
Par Pharmaceutical Companies, Inc. is a holding company that, principally through its wholly owned subsidiary, Par Pharmaceutical, Inc., is in the business of developing, manufacturing and distributing generic and branded drugs in the United States. The Company is divided into two business segments:... Full Description
Company Address
Par Pharmaceutical Companies, Inc.
300 Tice Boulevard
Woodcliff Lake NJ 07677
P: +1201.8024000
300 Tice Boulevard
Woodcliff Lake NJ 07677
P: +1201.8024000
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| Teva Pharmaceutical Industries Limited | ₪20,160.00 | 0.00 |
| Mylan Inc. | $17.98 | +0.43 |
| Watson Pharmaceuticals, Inc. | $35.68 | +0.53 |
| PRX | Industry | |
|---|---|---|
| P/E(TTM) | 22.25 | 3.57 |
| P/S(TTM) | 0.77 | 0.57 |
| ROI(TTM) | 7.34 | 1.86 |
| ROE(TTM) | 7.93 | 2.51 |
| Consensus Recommendation | Outperform |
|---|---|
| EPS Est. (Current Period) | 0.45 |
| EPS Est. (Current Year) | 2.46 |
| Total Revenue | $294.80M |
| Net Income | $26.51M |
| EPS | $0.77 |
